Cytokine News and Research

RSS

COVID-19 could accelerate activation of dormant tuberculosis (TB)

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).

10 May 2020

Study demonstrates dynamic and broad-scale immune alterations in COVID-19 patient

A new case report released on the preprint server medRxiv* provides a detailed longitudinal analysis of the immune response associated with a fatal case of coronavirus disease (COVID-19). It highlights the need for addressing the source of hyper inflammation in the treatment approach.

10 May 2020

NIH clinical trial evaluates antiviral plus anti-inflammatory drug for COVID-19

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019 (COVID-19) has begun.

8 May 2020

Researchers discover molecular mechanism that helps HSV1 infect the brain

Herpes simplex virus (HSV1) infections are initiated at mucosal surfaces where the virus infects epithelial cells.

8 May 2020

HMGB1 protein may play a key role in pulmonary inflammation, tissue damage in severe COVID-19 cases

In severe cases of COVID-19, a massive release of the endogenous protein HMGB1 in the lungs may contribute to pulmonary inflammation and tissue damage, according to a review article published today in the scientific journal Molecular Medicine.

8 May 2020

Repurposing existing drugs is a more rapid alternative than developing COVID-19 vaccine

Repurposing existing medicines focused on known drug targets is likely to offer a more rapid hope of tackling COVID-19 than developing and manufacturing a vaccine, argue an international team of scientists in the British Journal of Pharmacology today.

8 May 2020

Pangolins may be the key to new COVID-19 treatments

Researchers at the Medical University of Vienna, Austria, have made an important discovery about the immune response to coronaviruses in pangolins that could point to new approaches for treating human cases of infection.

8 May 2020

Vitamin D could improve outcomes in COVID-19

A new study published on the preprint server medRxiv* in May 2020 shows that vitamin D could have a beneficial effect on the course of illness for COVID-19 patients.

7 May 2020

Modified dialysis device treats COVID-19

As part of a randomized controlled trial, a team from Lawson Health Research Institute is the first in the world to treat a patient with COVID-19 using a modified dialysis device.

7 May 2020

Low CD8 and NK cell counts in the lung linked to high SARS-CoV-2 ACE2 receptor levels

A new study published on the preprint server bioRxiv in April 2020 reports that low levels of specific immune cells, namely, CD8 T cells and NK cells, are linked to higher expression of the ACE2 molecule, which acts as a receptor for the CoV.

6 May 2020

Interleukin-12 electroporation led to clinical responses in patients with advanced melanoma

Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.

6 May 2020

Cytokine storms created by COVID-19 could be reduced by using blood filter

Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.

6 May 2020

Study finds two FDA-approved drugs are promising against COVID-19

Korean researchers have screened 48 FDA-approved drugs against SARS-CoV-2, and found that two, that are already FDA-approved for other illnesses, seem promising.

5 May 2020

Uncovering immune cell reactions in COVID-19

A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.

4 May 2020

Researchers examine role of immune response in COVID-19 patients

A new USC study suggests that temporarily suppressing the body's immune system during the early stages of COVID-19 could help a patient avoid severe symptoms.

4 May 2020

Using Multiplex Assays to Discover Biomarkers for Parkinson’s Disease

In this interview, Dr. Polinski and Dr. Atabakhsh discuss the importance of developing biomarkers for Parkinson’s and the partnership between MJFF and Abcam.

From Abcam 1 May 2020

UK-based biotechnology firm discovers potential treatments for Covid-19

A UK-based biotechnology firm has announced the discovery of two separate novel treatments for Covid-19 patients before they are put on ventilators. They are now urgently seeking funding of £4m to accelerate safety studies and clinical trials.

30 Apr 2020

Temple University Hospital is offering COVID-19 clinical trials, investigational treatments options

Temple University Hospital is now participating in a variety of clinical trials that are testing investigational treatment options for patients diagnosed with the novel coronavirus, or COVID-19.

30 Apr 2020

Arthritis drug assessed as potential treatment for COVID-19-related pneumonia

UC San Diego Health has launched a Phase III clinical trial, part of a global effort, to assess whether a medication used to treat rheumatoid arthritis and other inflammatory disorders might also have therapeutic value for COVID-19 patients who have developed or at high risk of developing serious lung damage from SARS-CoV-2 infections.

29 Apr 2020

Researchers test existing anti-inflammatory drug in COVID-19 patients

An anti-inflammatory drug developed at Scripps Research 25 years ago is now being tested as a way to prevent acute respiratory distress in patients with COVID-19, the pandemic disease caused by the novel coronavirus.

29 Apr 2020